Identifying these relationships can reveal yet unknown mechanisms of DNA repair and new targets for therapy.
Introduction
Owing to the ubiquitous DNA damage occurring to cells and thus to the critical importance of DNA repair in maintaining genome stability, there is a great natural interest in understanding the physiology and pathophysiology behind these processes. Due to the large variety of potential lesions, resulting from either endogenous or exogenous sources, no single repair process can efficiently repair all types of DNA damage. Instead, multiple DNA repair mechanisms have evolved to protect the cells vital genetic information.
DNA lesions involving single strands may be repaired by various mechanisms. Global genome NER (GG NER) repairs along the entire genome, whereas transcription-coupled repair (TCR) takes care of damage that blocks the RNA polymerase (Lodish 2000 , Hoeijmakers 2001 , Houtsmuller et al. 1999 . Base excision repair (BER) is mostly directed towards repair of endogenous lesions due to cellular metabolism and is also activated by single strand breaks (SSB) (Lodish 2000, Barnes and Lindahl 2004) . DNA double strand breaks (DSB) resulting mainly from ionizing radiation, X-rays, free radicals and chemicals are solved by at least two pathways. Homologous recombination (HR) dominates in S and G2 phases, when DNA is replicated, providing a second copy of DNA for aligning, whereas non-homologous end joining (NHEJ) takes place mainly in the G1 phase of the cell cycle, when a second copy is not available.
Interestingly, almost identical processes to HR operate in chromosomal crossover during meiosis (Lodish 2000 , Hoeijmakers 2001 , Friedberg et al. 2006 . Furthermore, NHEJ is required for joining DSB induced during V(D)J recombination in B a T cell receptors.
The choice which repair system to use depends both on the type of lesion and on the cell-cycle phase of the cell (Branzei and Foiani 2008) . The cell-cycle machinery senses DNA damage and consecutively arrests at specific checkpoints in G1, S, G2 and M phases of the cell cycle to allow the repair of a lesion before its conversion into a permanent mutation.
Irreparable DNA damage may be inflicted when DNA repair mechanisms fail and cellular mechanisms leading to apoptosis do not occur.
DNA repair and cancer
Cancer is a genetic disease (Vogelstein and Kinzler 2004 importantly, the early detection and treatment of malignancies (Guinan et al. 1994 ).
However, due to the FA DNA repair defect, radiotherapy and chemotherapy have increased toxic side effects in patients with FA as compared to the general population and, if these agents are applied, dosage reduction is strongly recommended (Alter et al. 2002 , Taniguchi et al. 2006 , Hosoya et al. 2010 ).
The Fanconi Anemia pathway
Initially , 
Fanconi anemia mutations and solid cancers
Biallelic germline mutations in FA genes occur in patients with FA, but heterozygous germline mutations, somatic mutations and epigenetic silencing also occur in cancer patients 9 among the general population (non-FA patients) (Marsit et al. 2004 , Pejovic et al. 2006 , Dhillon et al. 2004 , Narayan G et al. 2004 , Taniguchi and DAndrea 2006 , Goggins et al. 1996 , Condie A et al. 2002 . 
Biallelic mutations of

Models to study the FA pathway
Several cancer-related genes are associated with specific types of cancer despite their ubiquitous function. 
Targeting DNA repair defects in cancer
Most anticancer drugs inhibit mitosis or DNA replication, thus killing rapidly dividing cells. However, when administered to patients, many will also injure rapidly dividing normal cells. Therapeutic index, the difference between the dose that gives a therapeutic effect and the dose that gives unacceptable toxicity, is often small. The aim of targeted therapy is to apply our increased understanding of the molecular signature of a tumor to develop drugs that exert a high efficiency only in targeted tumor cells, while exerting minimal toxicity in wildtype cells, thus enlarging the therapeutic window (Hucl et al 2007) .
Disruption of the FA pathway leads to defective DNA repair causing genomic instability and cancer progression. On the other hand, the cells gain a tumor-specific absolute biochemical difference (Hahn et al. 1996) . This difference between DNA repair-proficient Partial functional redundancy and cooperation of multiple pathways in repair of a particular lesion is illustrated by that fact that ICL repair involves at least three pathways, NER, TLS and HR (de Silva et al. 2000 , Zheng H et al. 2003 , Rothfuss et al. 2004 .
Similarly, DSBs repair involves HR, its variant SSA and NHEJ (Lodish 2000) .
Consequently, a defect in one pathway mechanism may lead to utilization, upregulation or even dependence on another pathway. Cells defective in FA pathway have been shown to have elevated NHEJ, SSA or TLS, suggesting possible candidates for synthetic lethality (Tutt et al. 2001) . Apart from these known alternative pathways, there may be yet unknown mechanisms of backup repair. In yeast, for example, a minor pathway involved in ICL repair has been described. This pathway involves Pso2 nuclease and may also be hyperactive in FA deficient human cells (Barber et al. 2001 ). SSB, PARP1 proficient cells will repair the defect using BER. In case o PARP1 deficiency, SSB will result in replication fork collapse requiring HR for repair. In BRCA2 proficient cells, HR recombination will be used, whereas BRCA2 deficiency will result in death. B.
Upon DSB, BRCA2 proficient cells will utilize HR for repair. BRCA2 deficient cells will turn to alternative error prone mechanisms of repair. Absence/inhibition of this alternative repair will result in death selectively in BRCA2 deficient cells. 
